CSIMarket


Becton Dickinson And Company  (BDX)
Other Ticker:  
 

Becton Dickinson's

Competitiveness


 

BDX Sales vs. its Competitors Q3 2021



Comparing the results to its competitors, Becton Dickinson reported Total Revenue increase in the 3 quarter 2021 by 7.36 % year on year.
The revenue growth was below Becton Dickinson's competitors average revenue growth of 12.16 %, recorded in the same quarter.

List of BDX Competitors

With net margin of 5.12 % company reported lower profitability than its competitors.

More on BDX Margin Comparisons



Revenue Growth Comparisons




Net Income Comparison


Becton Dickinson And Company Net Income in the 3 quarter 2021 grew year on year by 107.09 %, slower than its competitors income growth of 138.08 %

<<  More on BDX Income Comparisons


Becton Dickinson's Comment on Competitors and Industry Peers


BD operates in the increasingly complex and challenging medical technology marketplace. Technological advances and scientific discoveries have accelerated the pace of change in medical technology, the regulatory environment of medical products is becoming more complex and vigorous, and economic conditions have resulted in a challenging market. Companies of varying sizes compete in the global medical technology field. Some are more specialized than BD with respect to particular markets, and some have greater financial resources than BD. New companies have entered the field, particularly in the areas of molecular diagnostics, safety-engineered devices and in the life sciences, and established companies have diversified their business activities into the medical technology area.

Other firms engaged in the distribution of medical technology products have become manufacturers of medical devices and instruments as well. Acquisitions and collaborations by and among companies seeking a competitive advantage also affect the competitive environment. In addition, the entry into the market of manufacturers located in China and other low-cost manufacturing locations are creating increased pricing pressures, particularly in developing markets. Some competitors have also established manufacturing sites or have contracted with suppliers located in these countries as a means to lower their costs.
BD competes in this evolving marketplace on the basis of many factors, including price, quality, innovation, service, reputation, distribution and promotion.

The impact of these factors on BD’s competitive position varies among BD’s various product offerings. In order to remain competitive in the industries in which it operates, BD continues to make investments in research and development, quality management, quality improvement, product innovation and productivity improvement in support of its core strategy — to increase revenue growth by focusing on products that deliver greater benefits to patients, healthcare workers and researchers.





  

Overall company Market Share Q3 2021

Revenue in Overall company grew by 7.36 %, less than Becton Dickinson And Company peers within this division.

<<  More on BDX Market Share.
 

*Market share calculated with total revenue.


BDX's vs. Competition, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Becton Dickinson And Company 20,248 70,715 2,092 30,619
Amerisourcebergen Corp 213,989 24,617 1,545 14,000
Abbott Laboratories 42,308 233,053 7,244 77,000
Cardinal Health Inc 167,370 13,589 1,137 34,500
Carefusion Corp 3,556 0 368 16,000
Covidien Plc 10,880 0 1,605 39,500
Danaher Corporation 28,065 227,507 5,885 71,000
Hospira Inc 6,921 0 -8 0
Johnson and Johnson 91,446 426,326 17,880 126,500
Mckesson Corporation 250,991 34,067 -4,618 70,400
Medtronic Plc 31,797 144,841 4,731 49,000
Thermo Fisher Scientific Inc 39,059 252,536 8,565 51,000
Baxter International Inc 12,451 0 1,224 0
Helen Of Troy Limited 2,164 5,848 215 1,610
Honeywell International Inc 34,635 142,111 5,547 131,000
3m Company 35,326 101,190 5,979 89,800
Sigma Aldrich Corp 4,724 0 491 9,300
Adm Tronics Unlimited Inc 3 7 -1 21
Codexis inc 99 2,206 -17 106
Dupont De Nemours Inc 17,634 39,484 6,519 63,000
MEDIMMUNE, INC. 0 0 0 0
SUBTOTAL 1,013,666 1,718,095 66,382 874,356


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

TBD's Profile

Stock Price

TBD's Financials

Business Description

Fundamentals

Charts & Quotes

TBD's News

Suppliers

TBD's Competitors

Customers & Markets

Economic Indicators

TBD's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071